Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma

Summary

This is a single-arm, phase II trial of SOM230 in patients with documented recurrent or progressive intracranial meningioma who have failed conventional therapy and are not candidates for complete surgical resection of their tumors and/or radiation at the time of study entry. At the time of the final analysis, all patients who are receiving treatment with SOM230 will complete the core phase of the study and will continue on the extension phase. During this time, additional data on response duration, PFS, and safety will be collected.

Timeline

Start

2008-11

Primary completion

2013-03

Completion

2013-03

Drugs

Indications